{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:17:45Z","timestamp":1792783065286,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371811"],"award-info":[{"award-number":["82371811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shaanxi Province Natural Science Foundation","award":["2022JQ-962"],"award-info":[{"award-number":["2022JQ-962"]}]},{"name":"National Health Commission Chronic Disease Management and Prevention Program","award":["GWJJMB202510025095"],"award-info":[{"award-number":["GWJJMB202510025095"]}]},{"name":"First Affiliated Hospital of Xi\u2019an JiaoTong University Foundation","award":["2022MS-04"],"award-info":[{"award-number":["2022MS-04"]}],"id":[{"id":"https:\/\/ror.org\/02tbvhh96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Synovial fibroblasts (SFs) transform into an aggressive phenotype in rheumatoid arthritis (RA), playing a significant role in sustaining synovitis and bone erosion. Baricitinib, a JAK inhibitor, has been validated as an effective treatment for RA. However, its direct inhibitory effects on RASFs remain poorly understood. The inflammatory response and aggressive behaviors (proliferation, apoptosis, migration, and invasion) of RASFs were assessed following treatment with varying concentrations of baricitinib. RNA sequencing was performed to identify differentially expressed genes and elucidate the impact of baricitinib on RASFs. The relationship between the JAK-STAT3 signaling pathway and downstream molecules (EGR1, BCL-2, MMP-2, MMP-9) was analyzed via western blotting. Collagen-induced arthritis (CIA) mice were treated with baricitinib via oral gavage or by intra-articular injection of shEGR1 to evaluate therapeutic efficacy. Baricitinib inhibited the production of inflammatory mediators in primary RASFs and reduced the progression of synovial inflammation and hyperplasia in RA patients as assessed by ultrasound. In vitro, baricitinib promoted apoptosis and inhibited the proliferation, migration, and invasion of RASFs, effects associated with decreased expression of the transcriptional regulator EGR1. In vivo, baricitinib effectively reduced arthritis scores, paw swelling, and the expression of inflammatory cytokines in the joint tissues of CIA mice. Similar therapeutic effects were observed upon inhibition of EGR1. Baricitinib inhibits the aggressive phenotype of RASFs through the JAK-STAT3-EGR1 axis, thereby contributing to the alleviation of the inflammatory response and joint destruction in RA.<\/jats:p>","DOI":"10.1007\/s10753-026-02557-9","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:03:46Z","timestamp":1783465426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baricitinib Inhibits the Aggressive Phenotype of Synovial Fibroblasts in Rheumatoid Arthritis via the JAK-STAT3-EGR1 Axis"],"prefix":"10.1007","volume":"49","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuanYuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"10416","key":"2557_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo, A., J. M. Bathon, and P. Emery. 2023. Rheumatoid Arthritis Lancet 402(10416):2019\u20132033. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8","journal-title":"Rheumatoid Arthritis Lancet"},{"issue":"1","key":"2557_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","volume":"22","author":"CM Weyand","year":"2021","unstructured":"Weyand, C. M., and J. J. Goronzy. 2021. The Immunology of Rheumatoid Arthritis. Nature Immunology 22(1):10\u201318. https:\/\/doi.org\/10.1038\/s41590-020-00816-x","journal-title":"Nature Immunology"},{"issue":"7987","key":"2557_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","volume":"623","author":"F Zhang","year":"2023","unstructured":"Zhang, F., A. H. Jonsson, A. Nathan, N. Millard, M. Curtis, Q. Xiao, M. Gutierrez-Arcelus, W. Apruzzese, G. F. M. Watts, D. Weisenfeld, S. Nayar, J. Rangel-Moreno, N. Meednu, K. E. Marks, I. Mantel, J. B. Kang, L. Rumker, J. Mears, K. Slowikowski, K. Weinand, D. E. Orange, L. Geraldino-Pardilla, K. D. Deane, D. Tabechian, A. Ceponis, G. S. Firestein, M. Maybury, I. Sahbudin, A. Ben-Artzi, A. M. 2 Mandelin nd, A. Nerviani, M. J. Lewis, F. Rivellese, C. Pitzalis, L. B. Hughes, D. Horowitz, E. DiCarlo, E. M. Gravallese, and B. F. Boyce. 2023. Deconstruction of Rheumatoid Arthritis Synovium Defines Inflammatory Subtypes. Nature 623(7987):616\u2013624. https:\/\/doi.org\/10.1038\/s41586-023-06708-y. and the Accelerating Medicines Partnership: RA\/SLE Network.","journal-title":"Nature"},{"issue":"6","key":"2557_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","volume":"16","author":"G Nygaard","year":"2020","unstructured":"Nygaard, G., and G. S. Firestein. 2020. Restoring Synovial Homeostasis in Rheumatoid Arthritis by Targeting Fibroblast-Like Synoviocytes. Nature Reviews Rheumatology 16(6):316\u2013333. https:\/\/doi.org\/10.1038\/s41584-020-0413-5","journal-title":"Nature Reviews Rheumatology"},{"issue":"8","key":"2557_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1136\/annrheumdis-2021-222021","volume":"81","author":"T N\u00e9meth","year":"2022","unstructured":"N\u00e9meth, T., G. Nagy, and T. Pap. 2022. Synovial Fibroblasts as Potential Drug Targets in Rheumatoid Arthritis, Where Do We Stand and Where Shall We Go? Annals Of The Rheumatic Diseases 81(8):1055\u20131064. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222021","journal-title":"Annals Of The Rheumatic Diseases"},{"issue":"4","key":"2557_CR6","doi-asserted-by":"publisher","first-page":"e70152","DOI":"10.1002\/mco2.70152","volume":"6","author":"MA Samad","year":"2025","unstructured":"Samad, M. A., I. Ahmad, A. Hasan, M. H. Alhashmi, A. Ayub, F. A. Al-Abbasi, A. Kumer, and S. Tabrez. 2025. STAT3 Signaling Pathway in Health and Disease. MedComm (2020) 6(4):e70152. https:\/\/doi.org\/10.1002\/mco2.70152","journal-title":"MedComm (2020)"},{"key":"2557_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neuroscience.2021.02.011","volume":"487","author":"L Xie","year":"2022","unstructured":"Xie, L., Y. Wang, and Z. Chen. 2022. Early Growth Response Protein 1 Knockdown Alleviates the Cerebral Injury in Rats with Intracerebral Hemorrhage via STAT3\/NF-\u03baB Pathway by Reducing RXR\u03b1 Acetylation Level. Neuroscience 487:120\u2013130. https:\/\/doi.org\/10.1016\/j.neuroscience.2021.02.011","journal-title":"Neuroscience"},{"issue":"4","key":"2557_CR8","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.autrev.2023.103276","volume":"22","author":"M Benucci","year":"2023","unstructured":"Benucci, M., P. Bernardini, C. Coccia, R. De Luca, J. Levani, A. Economou, A. Damiani, E. Russo, A. Amedei, S. Guiducci, E. Bartoloni, M. Manfredi, V. Grossi, M. Infantino, and C. Perricone. 2023. JAK Inhibitors and Autoimmune Rheumatic Diseases. Autoimmun Rev 22(4):103276. https:\/\/doi.org\/10.1016\/j.autrev.2023.103276","journal-title":"Autoimmun Rev"},{"issue":"11","key":"2557_CR9","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux, Y., T. El Jammal, L. Vuitton, M. Gerfaud-Valentin, S. Kerever, and P. S\u00e8ve. 2019. JAK Inhibitors for the Treatment of Autoimmune and Inflammatory Diseases. Autoimmun Rev 18(11):102390. https:\/\/doi.org\/10.1016\/j.autrev.2019.102390","journal-title":"Autoimmun Rev"},{"issue":"4","key":"2557_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo, S., S. Nakayamada, and Y. Tanaka. 2023. JAK Inhibitors for Rheumatoid Arthritis. Expert Opinion On Investigational Drugs 32(4):333\u2013344. https:\/\/doi.org\/10.1080\/13543784.2023.2199919","journal-title":"Expert Opinion On Investigational Drugs"},{"issue":"7","key":"2557_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama, Z. T., and L. J. Scott. 2018. Baricitinib: A Review in Rheumatoid Arthritis. Drugs 78(7):761\u2013772. https:\/\/doi.org\/10.1007\/s40265-018-0908-4","journal-title":"Drugs"},{"issue":"7","key":"2557_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor, P. C., E. C. Keystone, D. van der Heijde, M. E. Weinblatt, L. Del Carmen Morales, J. Reyes Gonzaga, S. Yakushin, T. Ishii, K. Emoto, S. Beattie, V. Arora, C. Gaich, T. Rooney, D. Schlichting, W. L. Macias, S. de Bono, and Y. Tanaka. 2017. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. New England Journal Of Medicine 376(7):652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345","journal-title":"New England Journal Of Medicine"},{"issue":"3","key":"2557_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor, P. C., T. Takeuchi, G. R. Burmester, P. Durez, J. S. Smolen, W. Deberdt, M. Issa, J. R. Terres, N. Bello, and K. L. Winthrop. 2022. Safety of Baricitinib for the Treatment of Rheumatoid Arthritis over a Median of 4.6 and up to 9.3 Years of Treatment: Final Results from Long-Term Extension Study and Integrated Database. Annals Of The Rheumatic Diseases 81(3):335\u2013343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276","journal-title":"Annals Of The Rheumatic Diseases"},{"issue":"1","key":"2557_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13075-020-02379-6","volume":"23","author":"P Emery","year":"2021","unstructured":"Emery, P., P. Durez, A. J. Hueber, I. de la Torre, E. Larsson, T. Holzk\u00e4mper, and Y. Tanaka. 2021. Baricitinib Inhibits Structural Joint Damage Progression in Patients with Rheumatoid Arthritis\u2014A Comprehensive Review. Arthritis Res Ther 23(1):3. https:\/\/doi.org\/10.1186\/s13075-020-02379-6","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2557_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/1744666X.2022.2042254","volume":"18","author":"C Garufi","year":"2022","unstructured":"Garufi, C., M. Maclean, M. Gadina, and F. R. Spinelli. 2022. Affecting the Effectors: JAK Inhibitors Modulation of Immune Cell Numbers and Functions in Patients with Rheumatoid Arthritis. Expert Review Of Clinical Immunology 18(3):309\u2013319. https:\/\/doi.org\/10.1080\/1744666X.2022.2042254","journal-title":"Expert Review Of Clinical Immunology"},{"key":"2557_CR16","doi-asserted-by":"publisher","first-page":"607725","DOI":"10.3389\/fmed.2020.607725","volume":"7","author":"RA Moura","year":"2021","unstructured":"Moura, R. A., and J. E. Fonseca. 2021. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis. Front Med (Lausanne) 7:607725. https:\/\/doi.org\/10.3389\/fmed.2020.607725","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2557_CR17","doi-asserted-by":"publisher","first-page":"e002671","DOI":"10.1136\/rmdopen-2022-002671","volume":"9","author":"MH Nyirenda","year":"2023","unstructured":"Nyirenda, M. H., J. S. Nijjar, M. Frleta-Gilchrist, D. S. Gilchrist, D. Porter, S. Siebert, C. S. Goodyear, and I. B. McInnes. 2023. JAK Inhibitors Disrupt T Cell-Induced Proinflammatory Macrophage Activation. RMD Open 9(1):e002671. https:\/\/doi.org\/10.1136\/rmdopen-2022-002671","journal-title":"RMD Open"},{"key":"2557_CR18","doi-asserted-by":"publisher","first-page":"672461","DOI":"10.3389\/fimmu.2021.672461","volume":"12","author":"A O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, A., M. M. Hanlon, V. Marzaioli, S. C. Wade, K. Flynn, U. Fearon, and D. J. Veale. 2021. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function. Frontiers In Immunology 12:672461. https:\/\/doi.org\/10.3389\/fimmu.2021.672461","journal-title":"Frontiers In Immunology"},{"issue":"9","key":"2557_CR19","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.55563\/clinexprheumatol\/cfsajk","volume":"40","author":"S Weston","year":"2022","unstructured":"Weston, S., J. L. Macdonald, L. M. Williams, E. Roussou, N. V. Kang, S. Kiriakidis, and P. C. Taylor. 2022. The JAK Inhibitor Baricitinib Inhibits Oncostatin M Induction of Proinflammatory Mediators in Ex-Vivo Synovial Derived Cells. Clinical And Experimental Rheumatology 40(9):1620\u20131628. https:\/\/doi.org\/10.55563\/clinexprheumatol\/cfsajk","journal-title":"Clinical And Experimental Rheumatology"},{"issue":"11","key":"2557_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11547-019-01002-2","volume":"124","author":"E Filippucci","year":"2019","unstructured":"Filippucci, E., E. Cipolletta, R. Mashadi Mirza, M. Carotti, A. Giovagnoni, F. Salaffi, M. Tardella, A. Di Matteo, and M. Di Carlo. 2019. Ultrasound Imaging in Rheumatoid Arthritis. La Radiologia Medica 124(11):1087\u20131100. https:\/\/doi.org\/10.1007\/s11547-019-01002-2","journal-title":"La Radiologia Medica"},{"issue":"7","key":"2557_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","volume":"18","author":"N Komatsu","year":"2022","unstructured":"Komatsu, N., and H. Takayanagi. 2022. Mechanisms of Joint Destruction in Rheumatoid Arthritis \u2014 Immune Cell\u2013Fibroblast\u2013Bone Interactions. Nature Reviews Rheumatology 18(7):415\u2013429. https:\/\/doi.org\/10.1038\/s41584-022-00793-5","journal-title":"Nature Reviews Rheumatology"},{"key":"2557_CR22","doi-asserted-by":"publisher","unstructured":"Kugler, M., M. Dellinger, F. Kartnig, L. M\u00fcller, T. Preglej, L. X. Heinz, E. Simader, L. G\u00f6schl, S. E. Puchner, S. Weiss, L. E. Shaw, M. Farlik, W. Weninger, G. Superti-Furga, J. S. Smolen, G. Steiner, D. Aletaha, H. P. Kiener, M. J. Lewis, C. Pitzalis, A. Tosevska, T. Karonitsch, and M. Bonelli. 2023. Cytokine-Directed Cellular Cross-Talk Imprints Synovial Pathotypes in Rheumatoid Arthritis. Annals of the Rheumatic Diseases 82(9):1142\u20131152. https:\/\/doi.org\/10.1136\/ard-2022-223396","DOI":"10.1136\/ard-2022-223396"},{"issue":"1","key":"2557_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., J. Li, M. Fu, X. Zhao, and W. Wang. 2021. The JAK\/STAT Signaling Pathway: From Bench to Clinic. Signal Transduct Target Ther 6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1","journal-title":"Signal Transduct Target Ther"},{"key":"2557_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3389\/fimmu.2019.00541","volume":"10","author":"M Diller","year":"2019","unstructured":"Diller, M., R. Hasseli, M. L. H\u00fclser, I. Aykara, K. Frommer, S. Rehart, and U. M\u00fcller-Ladner, Neumann E. 2019. Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib. Frontiers In Immunology 10:541. https:\/\/doi.org\/10.3389\/fimmu.2019.00541","journal-title":"Frontiers In Immunology"},{"issue":"15","key":"2557_CR25","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.3390\/ijms25158327","volume":"25","author":"K Kie\u0142bowski","year":"2024","unstructured":"Kie\u0142bowski, K., P. Plewa, A. W. Bratborska, E. Bakinowska, and A. Pawlik. 2024. JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy. International Journal Of Molecular Sciences 25(15):8327. https:\/\/doi.org\/10.3390\/ijms25158327","journal-title":"International Journal Of Molecular Sciences"},{"key":"2557_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fmed.2020.00124","volume":"7","author":"B Burja","year":"2020","unstructured":"Burja, B., T. Mertelj, and M. Frank-Bertoncelj. 2020. Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis with JAK Inhibitors. Front Med (Lausanne) 7:124. https:\/\/doi.org\/10.3389\/fmed.2020.00124","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"2557_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-023-00966-w","volume":"19","author":"B Grillet","year":"2023","unstructured":"Grillet, B., R. V. S. Pereira, J. Van Damme, A. Abu El-Asrar, P. Proost, and G. Opdenakker. 2023. Matrix Metalloproteinases in Arthritis: Towards Precision Medicine. Nature Reviews Rheumatology 19(6):363\u2013377. https:\/\/doi.org\/10.1038\/s41584-023-00966-w","journal-title":"Nature Reviews Rheumatology"},{"key":"2557_CR28","doi-asserted-by":"publisher","first-page":"1100869","DOI":"10.3389\/fimmu.2023.1100869","volume":"14","author":"MA Murayama","year":"2023","unstructured":"Murayama, M. A., J. Shimizu, C. Miyabe, K. Yudo, and Y. Miyabe. 2023. Chemokines and Chemokine Receptors as Promising Targets in Rheumatoid Arthritis. Frontiers In Immunology 14:1100869. https:\/\/doi.org\/10.3389\/fimmu.2023.1100869","journal-title":"Frontiers In Immunology"},{"key":"2557_CR29","doi-asserted-by":"publisher","first-page":"114929","DOI":"10.1016\/j.bcp.2022.114929","volume":"197","author":"G Kour","year":"2022","unstructured":"Kour, G., R. Choudhary, S. Anjum, A. Bhagat, B. K. Bajaj, and Z. Ahmed. 2022. Phytochemicals Targeting JAK\/STAT Pathway in the Treatment of Rheumatoid Arthritis: Is There a Future? Biochemical Pharmacology 197:114929. https:\/\/doi.org\/10.1016\/j.bcp.2022.114929","journal-title":"Biochemical Pharmacology"},{"key":"2557_CR30","doi-asserted-by":"publisher","first-page":"115704","DOI":"10.1016\/j.bcp.2023.115704","volume":"215","author":"Y Mao","year":"2023","unstructured":"Mao, Y., X. Xie, T. Jiang, R. Chao, T. Wan, L. Sun, G. Sun, Z. Zhou, W. Xu, X. Chen, and S. Zhang. 2023. Xl019, a Novel JAK Inhibitor, Suppressed Osteoclasts Differentiation Induced by RANKL through MAPK Signaling Pathway. Biochemical Pharmacology 215:115704. https:\/\/doi.org\/10.1016\/j.bcp.2023.115704","journal-title":"Biochemical Pharmacology"},{"issue":"22","key":"2557_CR31","doi-asserted-by":"publisher","first-page":"e023539","DOI":"10.1161\/JAHA.121.023539","volume":"10","author":"LM Khachigian","year":"2021","unstructured":"Khachigian, L. M. 2021. Early Growth Response-1, an Integrative Sensor in Cardiovascular and Inflammatory Disease. J Am Heart Assoc 10(22):e023539. https:\/\/doi.org\/10.1161\/JAHA.121.023539","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2557_CR32","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1080\/15548627.2023.2281156","volume":"20","author":"MJ Livingston","year":"2024","unstructured":"Livingston, M. J., M. Zhang, S. H. Kwon, J. K. Chen, H. Li, S. Manicassamy, and Z. Dong. 2024. Autophagy Activates EGR1 via MAPK\/ERK to Induce FGF2 in Renal Tubular Cells for Fibroblast Activation and Fibrosis during Maladaptive Kidney Repair. Autophagy 20(5):1032\u20131053. https:\/\/doi.org\/10.1080\/15548627.2023.2281156","journal-title":"Autophagy"},{"key":"2557_CR33","doi-asserted-by":"publisher","first-page":"642547","DOI":"10.3389\/fonc.2021.642547","volume":"11","author":"B Wang","year":"2021","unstructured":"Wang, B., H. Guo, H. Yu, Y. Chen, H. Xu, and G. Zhao. 2021. The Role of the Transcription Factor EGR1 in Cancer. Frontiers In Oncology 11:642547. https:\/\/doi.org\/10.3389\/fonc.2021.642547","journal-title":"Frontiers In Oncology"},{"issue":"8","key":"2557_CR34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/onc.2012.127","volume":"32","author":"JC Cheng","year":"2013","unstructured":"Cheng, J. C., H. M. Chang, and P. C. Leung. 2013. Egr-1 Mediates Epidermal Growth Factor-Induced Downregulation of E-Cadherin Expression via Slug in Human Ovarian Cancer Cells. Oncogene 32(8):1041\u20131049. https:\/\/doi.org\/10.1038\/onc.2012.127","journal-title":"Oncogene"},{"issue":"1","key":"2557_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-020-06091-1","volume":"48","author":"SY Shin","year":"2021","unstructured":"Shin, S. Y., D. Koh, Y. Lim, and Y. H. Lee. 2021. Inhibition of EGR-1-Dependent MMP1 Transcription by Ethanol Extract of Ageratum houstonianum in HaCaT Keratinocytes. Molecular Biology Reports 48(1):1\u201311. https:\/\/doi.org\/10.1007\/s11033-020-06091-1","journal-title":"Molecular Biology Reports"},{"issue":"2","key":"2557_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/art.10774","volume":"48","author":"WK Aicher","year":"2003","unstructured":"Aicher, W. K., D. Alexander, C. Haas, S. Kuchen, A. Pagenstecher, S. Gay, H. H. Peter, and H. Eibel. 2003. Transcription Factor Early Growth Response 1 Activity Up-Regulates Expression of Tissue Inhibitor of Metalloproteinases 1 in Human Synovial Fibroblasts. Arthritis And Rheumatism 48(2):348\u2013359. https:\/\/doi.org\/10.1002\/art.10774","journal-title":"Arthritis And Rheumatism"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-026-02557-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-026-02557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-026-02557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:12:40Z","timestamp":1790809960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-026-02557-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2557"],"URL":"https:\/\/doi.org\/10.1007\/s10753-026-02557-9","relation":{},"ISSN":["1573-2576"],"issn-type":[{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Animal Experiment Ethics Committee of Xi\u2019an Jiaotong University. The human-related experiments complied with the Declaration of Helsinki and were approved by the Medical Ethics Committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University (No. XJTUAF2023LSK-147). Informed consent was obtained from all human participants.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for publication was obtained from all participants.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"192"}}